The induction of type I IFN needs to be tightly controlled, as it was shown in healthy individuals that inhalation of a TLR7 agonist was initially well tolerated after the first dose, but led to an increased TNF-α and IFN I response and influenza-like symptoms, after a second dose [43]. The gene discussed is TLR7; the disease is influenza.